Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH MATH 2020 | Update on auto-SCT for myeloma

Mohamad Mohty • 9 Jun 2020
IACH MATH 2020
Multiple Myeloma Bortezomib Carfilzomib Cyclophosphamide Daratumumab Dexamethasone Lenalidomide Melphalan Thalidomide

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, gives an update on the status of autologous stem cell transplant (auto-SCT) for multiple myeloma. Specifically, Prof. Mohty discusses the advances in induction therapy, the optimal conditioning regimen, as well as consolidation and maintenance therapy after auto-SCT. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Mohamad Mohty

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024

Related Videos

History and upcoming projects of the MMRF
Hearn Jay Cho et al. • 3 May 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
Novel targets & agents in myeloma
Faith Davies et al. • 3 May 2024
Session highlights: sequencing CAR-T cells & bispecifics and managing toxicities
Faith Davies et al. • 3 May 2024
The content of VJHemOnc is intended for healthcare professionals